← back to search

Yuan Zhou

Guangzhou University of Chinese Medicine · CN
Area of research
Nephrology · Epidemiology
Research interest
Research interests include Chronic Kidney Disease and Diabetes, Renal Diseases and Glomerulopathies, Ophthalmology and Visual Impairment Studies, and Acute Kidney Injury Research.
h-index
25
citations
2,083
works
76
NIH funding
primary concept
Medicine
email

Recent publications

The Pharmacokinetics, Pharmacological Mechanisms and Clinical Application of Zhenwu Decoction
Basic & Clinical Pharmacology & Toxicology 2025cited by 0position: middledoi
Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy
Phytomedicine 2023cited by 82position: middledoi
IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation
JCI Insight 2023cited by 51position: middledoi
Danshen injection induces autophagy in podocytes to alleviate nephrotic syndrome via the PI3K/AKT/mTOR pathway
Phytomedicine 2022cited by 41position: middledoi
Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps
Cell 2021cited by 332position: middledoi
JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes
European Journal of Pharmacology 2021cited by 82position: middledoi
Salvianolic acid B attenuates epithelial-mesenchymal transition in renal fibrosis rats through activating Sirt1-mediated autophagy
Biomedicine & Pharmacotherapy 2020cited by 65position: middledoi
Zhen-Wu-Tang Protects IgA Nephropathy in Rats by Regulating Exosomes to Inhibit NF-κB/NLRP3 Pathway
Frontiers in Pharmacology 2020cited by 45position: middledoi
Protective role of Astragaloside <scp>IV</scp> in chronic glomerulonephritis by activating autophagy through <scp>PI3K</scp>/<scp>AKT</scp>/<scp>AS160</scp> pathway
Phytotherapy Research 2020cited by 28position: middledoi
Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3β Pathway
Frontiers in Pharmacology 2019cited by 55position: middledoi
Paeoniflorin ameliorates Adriamycin-induced nephrotic syndrome through the PPARγ/ANGPTL4 pathway in vivo and vitro
Biomedicine & Pharmacotherapy 2017cited by 43position: middledoi
Effect of Maxing Shigan Tang on H1N1 Influenza A Virus-Associated Acute Lung Injury in Mice
Intervirology 2016cited by 22position: middledoi
Extraction of Iron from the Rabbit Anterior Chamber with Reverse Iontophoresis
Journal of Ophthalmology 2015cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jiuyao Zhou · Guangzhou University of Chinese Medicine9 papers (2016–2025)Bihao Liu · Sun Yat-sen University7 papers (2016–2023)Ruirui Lu · Shandong University7 papers (2016–2021)Junqi Chen · Guangzhou University of Chinese Medicine5 papers (2020–2023)Junbiao Wu · Guangzhou University of Chinese Medicine5 papers (2019–2021)Yiwen Cao · Guangzhou University of Chinese Medicine4 papers (2020–2025)Peichun Zhang · Guangzhou University of Chinese Medicine3 papers (2017–2020)Dandan Chen · Shandong University3 papers (2019–2021)Ji‐Cheng Li · Guangzhou University of Chinese Medicine3 papers (2020–2020)Honglian Li · Guangzhou University of Chinese Medicine3 papers (2019–2020)Lixia Bai · Guangzhou University of Chinese Medicine3 papers (2017–2020)Yu He · First Affiliated Hospital of Xi'an Jiaotong University3 papers (2016–2020)Hong Liu · Guangzhou University of Chinese Medicine2 papers (2022–2023)Xueping Guan · Guangzhou University of Chinese Medicine2 papers (2022–2023)Shengliang Yuan · Guangzhou University of Chinese Medicine2 papers (2022–2023)Hua Lin · Guangzhou University of Chinese Medicine2 papers (2020–2021)Yanchun Zhong · Guangzhou University of Chinese Medicine2 papers (2016–2017)Simin Yin · Guangzhou University of Chinese Medicine2 papers (2022–2023)Yu Pang · Guangzhou University of Chinese Medicine2 papers (2020–2020)Yifan Wu · Huazhong University of Science and Technology2 papers (2019–2021)